Turning Point Therapeutics Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. 's patritumab deruxtecan (DXd) in June, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab

The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s patritumab deruxtecan (DXd) this week, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotama

A second approval for Bristol Myers Squibb Company ’s cancer drug Augtyro (repotrectinib) has provided further validation of BMS’s $4.1bn acquisition of Turning Point Therapeutics Inc. in 2022. [Si